In one of two companion diagnostics deals it signed on the same day, Roche Diagnostics Corp.’s Ventana Medical Systems Inc. (tissue analysis) will create a test for oncology drug developer AEterna Zentaris Inc.’s AEZS108 for the immunohistochemical determination of luteinizing hormone-release hormone (LHRH) receptor expression. (Jan.)
AEterna will use this diagnostic to select ideal patients for AEZS108, a Phase II formulation of doxorubicin which is conjugated to a synthetic peptide (zoptarelin) that directs chemotherapy specifically to LHRH-positive tumors, and avoids healthy cells. To date, AEZS108 has been studied in advanced endometrial, advanced ovarian, castration-refractory prostate, and refractory bladder cancers. (For the ovarian cancer indication, the candidate has orphan drug status in the US and EU.) AEterna also plans to develop AEZS108 for triple-negative breast cancer
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?